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Douglas L. Mann, MD, FACC, L. Kristin Newby, MD, FACCP resident Obama announced in his 2015 State ofthe Union address that he was launching thePrecision Medicine Initiative (PMI), calling it
“a bold new research effort to revolutionize how we
improve health and treat disease” (1). Under the aus-
pices of the PMI, the National Institutes of Health will
create a U.S. cohort of 1million participantswho volun-
tarily contribute information about their medical and
social history, environment, and life-style and provide
biospecimens for genetic and other future molecular
characterization. This information will ultimately be
available to the scientiﬁc community with the hope
that it will be used to develop novel new therapies
and identify novel approaches to disease prevention.
In parallel, the National, Heart, Lung, and Blood Insti-
tute has developed a major research initiative, Trans-
Omics for Precision Medicine (TOPMed), that will
“couple whole-genome sequencing (WGS) and other
-omics data withmolecular, behavioral, imaging, envi-
ronmental, and clinical data from studies focused on
heart, lung, blood and sleep disorders” (2). The long-
term goal of TOPMed is to uncover factors that “in-
crease or decrease the risk of disease, identify subtypes
of disease, and develop more targeted and personal-
ized treatments” (2). Concurrently, the U.S. Food and
Drug Administration (FDA) has created the preci-
sionFDA initiative to facilitate the development and
standardization of next-generation precision diag-
nostics and inform advances in regulatory science to
beneﬁt individuals and public health. The goal of pre-
cisionFDA is to create a “community research and de-
velopment portal that allows for testing, piloting, and
validating existing andnewbioinformatics approaches
to next generation sequence processing” (3).With all of
the excitement around these big science initiativesFrom the American College of Cardiology, Washington, DC.and precision health care, it is appropriate to question
whether these new programs will accelerate transla-
tional research efforts to develop new drugs and de-
vices for patients afﬂictedwith cardiovascular disease.
Unlike cancer, the efforts thus far to use genomic
data to inform the development of personalized car-
diovascular therapeutics have been promissory. The
PersonalizedMedicine Coalition reported that 13 of the
45 novel new drugs approved by the FDA’s Center for
Drug Evaluation and Research in 2015 could be classi-
ﬁed as “personalized medicines” (4). A total of 5 of
the 13 new drugs classiﬁed as personalized medicines
were oncology drugs, accounting for 35% of the new
oncology drugs approved by the FDA in 2015. By way
of comparison, only 4 novel new cardiovascular drugs
were approved by the FDA in 2015, none of which were
classiﬁed as personalized medicines. Perhaps more
sobering is the realization thatmore than adecade after
the completion of the Human Genome Project, we still
do not have a single new life-extending cardiovascular
treatment emanating from this nearly $3 billion effort.
As a result, many skeptics have argued that, analogous
to the Human Genome Project, the champions of PMI
are overpromising on the deliverables. Given the
glacial progress in the cardiovascular space thus far,
this argument is certainly understandable.
Notwithstanding the discovery of PCSK9 (5,6) and
the elegant translational efforts that followed (7), our
ability to use “omic” technologies to develop novel
cardiovascular therapeutics has been slow in compar-
ison with the development of novel new cancer drugs.
In this regard, the PMI may create several exciting new
opportunities for cardiovascular translational in-
vestigators. First, the ability to use high-dimensional
genomic data should provide a unique opportunity
to identify enriched patient populations for future
treatment trials, as well as novel drug targets. As 1 po-
tential example, a post-hoc genome-wide association
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6 Mann and Newby
J U N E 2 0 1 6 : 2 9 8 – 9 Editor’s Page
299study of patients from the dalcetrapib arm of the dal-
OUTCOMES trial, which was neutral with respect to
the primary endpoint (8), identiﬁed a unique group of
responderswho had a single nucleotide polymorphism
in the ADCY9 gene (9). This pharmacogenomics anal-
ysis formed the rationale for the forthcoming 5,000-
patient phase 3 multicenter trial (Effect of Dalcetrapib
vs Placebo on CV Risk in a Genetically Deﬁned Popu-
lation With a Recent ACS [dal-GenE]; NCT02525939)
that will examine the effects of dalcetrapib in subjects
recently hospitalized for an acute coronary syndrome
who have the appropriate genetic proﬁle. Second, the
precisionFDA initiative will promote standardization
of next-generation sequencing platforms, which in
turn will allow investigators to combine genetic in-
formation obtained from multiple datasets. Third, the
National, Heart, Lung, and Blood Institute’s TOPMed
initiative will develop the requisite infrastructure to
create data warehouses from existing well-curated
patient cohorts (e.g., Framingham Heart Study and
the Jackson Heart Study), enabling investigators to
combine phenotypic, genomic, and sociocultural data
in a heretofore unprecedented manner. The use of
these integrated data platforms may allow researchers
to better understand how subjects respond to con-
ventional cardiovascular therapies and may offer the
possibility to better understand how interactions
among comorbidities, life-styles, and sociocultural
backgrounds inﬂuence the outcomes of individuals
with a given genetic proﬁle. Although transgenic
animal models have provided invaluable mechanistic
insights into diseases and permit rigorous mechanistic
experimentation, they are less valuable for trans-
lational efforts. Transgenic mice are highly inbred
and lack the genetic heterogeneity in humans, and
laboratory environments lack the diversity of human
environmental exposures. Mice are also devoid of
the types of comorbidities that negatively inﬂu-
ence the outcomes of patients with cardiovasculardiseases. Fourth, the ability to perform whole genome
sequencing in different patient populations will allow
scientists to better understand the natural conse-
quences of gain- or loss-of-function mutations in
genes that are associated with different cardiovascular
diseases. Thus, the PMI should provide a unique op-
portunity to better understand the drivers of human
disease and to potentially identify new cardiovascular
drug targets.
WILL THE PMI TRANSFORM CARDIOVASCULAR
TRANSLATIONAL RESEARCH?
At this point in the life cycle of the PMI, any attempt to
answer this question would be completely hypotheti-
cal. Further, given that the majority of cardiovascular
diseases are inﬂuenced by multiple genes and macro-
environmental and microenvironmental features, the
road ahead for cardiovascular translationalists will
likely have considerablymore twists, turns, andbumps
than the road traversed by our translational colleagues
in oncology. However, with that said, the PMI will
place a new set of unique tools and techniques in the
hands of both cardiovascular investigators in academia
and industry, as well as patient advocacy groups.
Although these new tools and the opportunities they
bring may not be transformative immediately, they
will certainly advance the ﬁeld in a number of exciting
and unforeseen ways in the coming years. As always,
we welcome your thoughts, and would like to hear
what you think about the effect of the PMI on cardio-
vascular translational medicine, either through social
media (#JACCBTS) or by e-mail (jaccbts@acc.org).
ADDRESS CORRESPONDENCE TO: Dr. Douglas L.
Mann, Washington University, Internal Medicine,
Cardiovascular Division, 660 South Euclid Avenue,
Campus Box 8086, St. Louis, Missouri 63110. E-mail:
jaccbts@acc.org.RE F E RENCE S1. Obama B. The Precision Medicine Initiative.
2015. Available at: https://www.whitehouse.gov/
precision-medicine. Accessed May 19, 2016.
2. National Heart, Lung, and Blood Institute.
Trans-Omics for Precision Medicine (TOPMed)
program. 2015. Available at: http://www.nhlbi.
nih.gov/research/resources/nhlbi-precision-medicine-
initiative/topmed. Accessed May 19, 2016.
3. U.S. Food and Drug Administration. FDA’s
role in the Precision Medicine Initiative. 2015.
Available at: http://www.fda.gov/ScienceResearch/
SpecialTopics/PrecisionMedicine/default.htm. Accessed
May 19, 2016.4. Personalized Medicine Coalition. 2015 progress
report: personalized medicine at FDA. 2015. Avail-
able at: http://www.personalizedmedicinecoalition.
org/News/Press_Releases/More_Than_1_in_4_Novel_New_
Drugs_Approved_by_FDA_in_2015_are_Personalized_
Medicines. Accessed May 19, 2016.
5. Abifadel M, Varret M, Rabes JP, et al. Mu-
tations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet 2003;34:
154–6.
6. Cohen J, Pertsemlidis A, Kotowski IK, Graham R,
Garcia CK, Hobbs HH. Low LDL cholesterol in in-
dividuals of African descent resulting fromfrequent nonsense mutations in PCSK9. Nat Genet
2005;37:161–5.
7. Seidah NG, Awan Z, Chretien M, Mbikay M.
PCSK9: a key modulator of cardiovascular health.
Circ Res 2014;114:1022–36.
8. Schwartz GG, Olsson AG, Abt M, et al. Ef-
fects of dalcetrapib in patients with a recent
acute coronary syndrome. N Engl J Med 2012;
367:2089–99.
9. Tardif JC, Rheaume E, Lemieu Perreault LP,
et al. Pharmacogenomic determinants of the car-
diovascular effects of dalcetrapib. Circ Genetics
2015;8:10.
